Advancements in Prostate Cancer Research

Displaying 1 - 18 of 18CSV
De Felice, D., Alaimo, A., Bressan, D., Genovesi, S., Marmocchi, E., Annesi, N., Beccaceci, G., Dalfovo, D., Cutrupi, F., Medaglia, S., Foletto, V., Lorenzoni, M., Gandolfi, F., Kannan, S., Verma, C. S., Vasciaveo, A., Shen, M. M., Romanel, A., Chiacchiera, F., … Lunardi, A. (2024). Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer. EMBO Reports. https://doi.org/10.1038/s44319-024-00335-y
Publication Date
Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005
Publication Date
Leuva, H., Zhou, M., Jamaleddine, N., Meseha, M., Faiena, I., Anna Park, Y.-H., McWilliams, G., Luhrs, C., Maxwell, K. N., Von Hoff, D., Bates, S. E., & Fojo, T. (2024). Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent -rate method ideal for real-world analyses. EBioMedicine, 107, 105288. https://doi.org/10.1016/j.ebiom.2024.105288
Publication Date
Carmichael, J., Figueiredo, I., Gurel, B., Beije, N., Yuan, W., Rekowski, J., Seed, G., Carreira, S., Bertan, C., Fenor de la Maza, M. de L. D., Chandran, K., Neeb, A., Welti, J., Gallagher, L., Bogdan, D., Crespo, M., Riisnaes, R., Ferreira, A., Miranda, S., … de Bono, J. (2024). RNASEH2B loss and PARP inhibition in advanced prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci178278
Publication Date
Rayn, K., Deutsch, I., Jeffers, B., Lee, A., Lavrova, E., Gallitto, M., Mayeda, M., Hwang, M., Yu, J., Spina, C., & Koutcher, L. (2024). Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer. Advances in Radiation Oncology, 9(3), 101408. https://doi.org/10.1016/j.adro.2023.101408
Publication Date
Stein, M. N., Hawley, J., Zibelman, M., Pachynski, R., Dreicer, R., Zarrabi, K. K., Miles, B., Hauke, R. J., Marshall, M. A., Jones, B., Wheeler, V., Sebastian, S., Anderson, K., Vardeu, A., Davis, C., Bendall, J., & Shore, N. (2023). 665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0665
Publication Date
Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006
Publication Date
Baljevic, M., Moreau, P., Tuchman, S., Callander, N., Lentzsch, S., Van Domelen, D., Bentur, O., Monge, J., & Biran, N. (2023). P-232 Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clinical Lymphoma Myeloma and Leukemia, 23, S163. https://doi.org/10.1016/s2152-2650(23)01850-5
Publication Date
Madan, R. A., Bilusic, M., Stein, M. N., Donahue, R. N., Arlen, P. M., Karzai, F., Plimack, E., Wong, Y.-N., Geynisman, D. M., Zibelman, M., Mayer, T., Strauss, J., Chen, G., Rauckhorst, M., McMahon, S., Couvillon, A., Steinberg, S., Figg, W. D., Dahut, W. L., … Gulley, J. L. (2023). Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist, 28(7), 642-e561. https://doi.org/10.1093/oncolo/oyad058
Publication Date
Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342
Publication Date
Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer. (2022). Cellular Physiology and Biochemistry, 56(S4), 1–15. https://doi.org/10.33594/000000592
Publication Date
Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733
Publication Date
Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668
Publication Date
Kim, M. S., Naidoo, D., Hazra, U., Quiver, M. H., Chen, W. C., Simonti, C. N., Kachambwa, P., Harlemon, M., Agalliu, I., Baichoo, S., Fernandez, P., Hsing, A. W., Jalloh, M., Gueye, S. M., Niang, L., Diop, H., Ndoye, M., Snyper, N. Y., Adusei, B., … Lachance, J. (2022). Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 23(1). https://doi.org/10.1186/s13059-022-02766-z
Publication Date
Lim, E., Reeves, J., Gandhi, S., Spigel, D. R., Arrowsmith, E., George, D. J., Karlix, J., Pouliot, G., Hattersley, M., Gangl, E., James, G., Thompson, J., Russell, D., Patel, B., Kumar, R., & Falchook, G. S. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 33, S1182–S1183. https://doi.org/10.1016/j.annonc.2022.07.1882
Publication Date
Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048
Publication Date
Cambuli, F., Foletto, V., Alaimo, A., De Felice, D., Gandolfi, F., Palumbieri, M. D., Zaffagni, M., Genovesi, S., Lorenzoni, M., Celotti, M., Bertossio, E., Mazzero, G., Bertossi, A., Bisio, A., Berardinelli, F., Antoccia, A., Gaspari, M., Barbareschi, M., Fiorentino, M., … Lunardi, A. (2022). Intra‐epithelial non‐canonical Activin A signaling safeguards prostate progenitor quiescence. EMBO Reports, 23(5). Portico. https://doi.org/10.15252/embr.202154049
Publication Date